Literature DB >> 22888163

Cardiac transthyretin amyloidosis.

Jason N Dungu1, Lisa J Anderson, Carol J Whelan, Philip N Hawkins.   

Abstract

Cardiac amyloidosis of transthyretin fibril protein (ATTR) type is an infiltrative cardiomyopathy characterised by ventricular wall thickening and diastolic heart failure. Increased access to cardiovascular magnetic resonance imaging has led to a marked increase in referrals to our centre of Caucasian patients with wild-type ATTR (senile systemic) amyloidosis and Afro-Caribbean patients with the hereditary ATTR V122I type. Both subtypes present predominantly as isolated cardiomyopathy. The differential diagnosis includes cardiac amyloid light-chain (AL) amyloidosis, which has a poorer prognosis and can be amenable to chemotherapy. We review here the clinical features of cardiac ATTR amyloidosis and describe the diagnostic tests to determine ATTR type. Correct diagnosis is ever more crucial given that several novel therapies for ATTR amyloidosis are on the near horizon.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22888163     DOI: 10.1136/heartjnl-2012-301924

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  29 in total

Review 1.  Cardiohepatic syndrome.

Authors:  Gerhard Poelzl; Johann Auer
Journal:  Curr Heart Fail Rep       Date:  2015-02

2.  Role of imaging in cardiac amyloidosis: An ongoing challenge.

Authors:  Ashutosh D Wechalekar
Journal:  J Nucl Cardiol       Date:  2015-11-05       Impact factor: 5.952

Review 3.  2021 Advocacy Statements for the Role of 99mTc-Pyrophosphate Scintigraphy in the Diagnosis of Transthyretin Cardiac Amyloidosis: A Report of the Taiwan Society of Cardiology and the Society of Nuclear Medicine of the Republic of China.

Authors:  Yih-Hwen Huang; Yen-Hung Lin; Ruoh-Fang Yen; Charles Jia-Yin Hou; Shan-Ying Wang; Shih-Chuan Tsai; Kung-Chu Ho; Ming-Hsien Lin; Chin-Ho Tsao; Chih-Yung Chang; Jin-Long Huang; Mei-Fang Cheng; Yen-Wen Wu
Journal:  Acta Cardiol Sin       Date:  2021-05       Impact factor: 2.672

Review 4.  Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies.

Authors:  Kavita Sharma; David A Kass
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

5.  Predictors of survival stratification in patients with wild-type cardiac amyloidosis.

Authors:  F Aus dem Siepen; R Bauer; A Voss; S Hein; M Aurich; J Riffel; D Mereles; C Röcken; S J Buss; H A Katus; Arnt V Kristen
Journal:  Clin Res Cardiol       Date:  2017-09-27       Impact factor: 5.460

6.  Role of domain interactions in the aggregation of full-length immunoglobulin light chains.

Authors:  Enrico Rennella; Gareth J Morgan; Jeffery W Kelly; Lewis E Kay
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-31       Impact factor: 11.205

7.  Case 3/2014--81-year-old patient hospitalized for decompensated heart failure.

Authors:  Bruna Affonso Madaloso; Paulo Sampaio Gutierrez
Journal:  Arq Bras Cardiol       Date:  2014-07       Impact factor: 2.000

Review 8.  Novel drugs targeting transthyretin amyloidosis.

Authors:  Mazen Hanna
Journal:  Curr Heart Fail Rep       Date:  2014-03

Review 9.  Clinical Applications of Echo Strain Imaging: a Current Appraisal.

Authors:  Agostina M Fava; Dane Meredith; Milind Y Desai
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-08-31

10.  Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction.

Authors:  Selma F Mohammed; Sultan A Mirzoyev; William D Edwards; Ahmet Dogan; Donna R Grogan; Shannon M Dunlay; Veronique L Roger; Morie A Gertz; Angela Dispenzieri; Steven R Zeldenrust; Margaret M Redfield
Journal:  JACC Heart Fail       Date:  2014-04       Impact factor: 12.035

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.